Experimental Pill Nearly Doubles Survival Rates
A phase 3 clinical trial shows that the drug daraxonrasib significantly improves survival rates for patients with advanced pancreatic cancer. The study found that the drug reduced the risk of death by 60% compared to standard chemotherapy.
Why it matters
This represents a potential breakthrough in treating pancreatic cancer, which has historically had very low survival rates.
In a phase 3 clinical trial, the drug daraxonrasib significantly improved survival rates of participants with pancreatic cancer who had previously been treated with chemotherapy.
The article reports on medical trial results published in a peer-reviewed journal.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in